© Pixabay

French immunotherapy specialist Neovacs raises 6€m from three US institutional investors. The private placement involves the issuance of more than 9 million shares.

© Bavarian Nordic

Johnson & Johnson has entered a new deal with Danish biotech Bavarian Nordic worth up to US$879m to develop vaccine regimens against hepatitis B and HIV.

© GSK

UK’s biggest pharma firm announced it will save an additional £1bn each year by 2020. 80% of the pharmaceutical R&D pipeline expenses will be directed towards two current (Respiratory and HIV/infectious diseases) and two potential (Oncology and Immuno-inflammation) priority areas.

© Dr. Graham Beards

French yeast manufacturer Lesaffre acquires an equity stake in US biotech company Intralytix. Paying more than €15m, Lesaffre gains valuable insights into the development and commercialisation of bacteriophage-based products.

© Arjona Ferreira / Myovant Sciences

Swiss-based pharmaceutical company Myovant Sciences Ltd. is adding four new executives. Among them is a new Chief Medical Director, Juan Camilo Arjona Ferreira. In addition, the company increases its competence in regulatory affairs.

© Centers for Disease Control and Prevention's Public Health Image Library / Janice Haney CarrContent

French Antabio receives funding by the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X). Including future milestone payments, Antabio is eligible for up to €7.6m for their treatment of chronic infections in cystic fibrosis patients.

© Lisa Berg

British pharma company GlaxoSmithKline plc. is expanding its company board and announced Laurie Glimcher as a non-executive director. Glimcher will join the board on 1 September.

© Pixabay

French vaccines expert Valneva SE announced that the FDA has granted Fast Track designation for its Lyme borreliosis vaccine candidate VLA15.

Daniel Oliver , Founder. © Capital Cell

Spanish Capital Cell was one of the first equity crowdfunding platforms that specialised in life sciences and biotech projects in Europe. In March, the group raised more than €1m through funding through the Spanish biotech campaign Bionure a new record. EuroBiotech talked to Capital Cell founder Daniel Oliver about their recent expansion into the UK and the development of the European life sciences crowdfunding scene. 

© Oryzon Genomics S.A.

After 3 years of collaboration Roche has ended a cancer deal with the Spanish biotech company Oryzon granting the rights to their cancer candidate ORY-1001.